TY - JOUR
T1 - miRNA regulation of LDL-cholesterol metabolism
AU - Goedeke, Leigh
AU - Wagschal, Alexandre
AU - Fernández-Hernando, Carlos
AU - Näär, Anders M.
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health (R01DK094184 and U54HL119145 to AMN and R01HL107953 and R01HL106063 to CF-H) and The Leducq Transatlantic Network in Vascular microRNAs (MIRVAD) to CF-H. Fig. 1 was generated using the Servier Medical Art illustration resources ( http://www.servier.com ). We apologize to those whose work could not be cited due to space limitations.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - In the past decade, microRNAs (miRNAs) have emerged as key regulators of circulating levels of lipoproteins. Specifically, recent work has uncovered the role of miRNAs in controlling the levels of atherogenic low-density lipoprotein LDL (LDL)-cholesterol by post-transcriptionally regulating genes involved in very low-density lipoprotein (VLDL) secretion, cholesterol biosynthesis, and hepatic LDL receptor (LDLR) expression. Interestingly, several of these miRNAs are located in genomic loci associated with abnormal levels of circulating lipids in humans. These findings reinforce the interest of targeting this subset of non-coding RNAs as potential therapeutic avenues for regulating plasma cholesterol and triglyceride (TAG) levels. In this review, we will discuss how these new miRNAs represent potential pre-disposition factors for cardiovascular disease (CVD), and putative therapeutic targets in patients with cardiometabolic disorders. This article is part of a Special Issue entitled: MicroRNAs and lipid/energy metabolism and related diseases edited by Carlos Fernández-Hernando and Yajaira Suárez.
AB - In the past decade, microRNAs (miRNAs) have emerged as key regulators of circulating levels of lipoproteins. Specifically, recent work has uncovered the role of miRNAs in controlling the levels of atherogenic low-density lipoprotein LDL (LDL)-cholesterol by post-transcriptionally regulating genes involved in very low-density lipoprotein (VLDL) secretion, cholesterol biosynthesis, and hepatic LDL receptor (LDLR) expression. Interestingly, several of these miRNAs are located in genomic loci associated with abnormal levels of circulating lipids in humans. These findings reinforce the interest of targeting this subset of non-coding RNAs as potential therapeutic avenues for regulating plasma cholesterol and triglyceride (TAG) levels. In this review, we will discuss how these new miRNAs represent potential pre-disposition factors for cardiovascular disease (CVD), and putative therapeutic targets in patients with cardiometabolic disorders. This article is part of a Special Issue entitled: MicroRNAs and lipid/energy metabolism and related diseases edited by Carlos Fernández-Hernando and Yajaira Suárez.
KW - GWAS
KW - LDL
KW - LDLR
KW - cholesterol
KW - lipid
KW - miRNA
UR - http://www.scopus.com/inward/record.url?scp=84961219327&partnerID=8YFLogxK
U2 - 10.1016/j.bbalip.2016.03.007
DO - 10.1016/j.bbalip.2016.03.007
M3 - Article
C2 - 26968099
AN - SCOPUS:84961219327
SN - 1388-1981
VL - 1861
SP - 2047
EP - 2052
JO - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
JF - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
IS - 12
ER -